Temisis Therapeutics competitors and similar companiesClear all

Temisis Therapeutics's competitors and similar companies include Kamada Pharmaceuticals, Sosei Heptares and Camurus.

	Temisis Therapeutics Temisis Therapeutics is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing an inflammatory component.	Kamada Pharmaceuticals Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications.	Sosei Heptares Sosei Heptares is a biopharmaceutical company that specializes in drug development.	Camurus Camurus is a research-based pharmaceutical company that develops medicines for severe and chronic conditions.
Founding Date	Founding Date N/A	Founding Date 1990	Founding Date 1990	Founding Date 1991
Type	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy
Locations	Locations Vandœuvre-lès-Nancy, FR HQ	Locations Rehovot, IL HQ Beit Kama, IL	Locations Tokyo, JP HQ Dublin, IE Cambridge, GB London, GB	Locations Lund, SE HQ Sydney, AU Mannheim, DE Duxford, GB
Employees	Employees 2	Employees 3807% increase	Employees 199	Employees 157
Valuation ($)	Valuation ($) N/A	Valuation ($) 213.3 m	Valuation ($) 1.8 b	Valuation ($) 1.4 b
Employee Rating	Employee Rating N/A	Employee Rating 3.5	Employee Rating 3.9	Employee Rating 5
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $129.3m (FY, 2022)	Revenue (est.) ¥15.6b (FY, 2022)	Revenue (est.) kr956.3m (FY, 2022)
Cost of goods	Cost of goods N/A	Cost of goods $59.1m (FY, 2022)	Cost of goods ¥490m (FY, 2022)	Cost of goods kr90.2m (FY, 2022)
Gross profit	Gross profit N/A	Gross profit $70.2m (FY, 2022)	Gross profit ¥15.7b (FY, 2022)	Gross profit kr866.9m (FY, 2022)
Net income	Net income N/A	Net income ($2.3m) (FY, 2022)	Net income ¥1.8b (FY, 2022)	Net income kr55.6m (FY, 2022)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 90m	Total funding raised $ 65m	Total funding raised N/A